United States (National)
Not enough data
Phalguni Deswal's coverage is heavily focused on the Healthcare & Pharmaceutical industry, particularly around announcements and data citations related to neurology, MedTech, pharmaceuticals, clinical trials, and healthcare technology. Given this focus, she would likely be most responsive to pitches that offer in-depth insights into groundbreaking developments within these areas.
She seems receptive to detailed data-driven analysis and may also welcome commentary from experts who can provide valuable context or industry-specific knowledge. Pitches offering unique perspectives on acquisitions, FDA reviews of medications or medical devices could align well with her coverage.
Since there is no specified geographic focus for Phalguni's work, it suggests a global perspective on healthcare and pharmaceutical topics may be relevant when reaching out to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Phalguni Deswal
With FDA clearance for its SPARC pivotal trial, CEO Scott Nelson is betting that a physician-first design—circumferential energy, a faster pulse, and a workflow built for office-based labs—can set the Artero electric IVL system apart from a field of deep-pocketed rivals.
By: Phalguni Deswal
Medical device giant hit by cybersecurity incident on Aug. 25, triggering network outages, shipment disruptions and work-from-home orders for thousands of employees. The scope, data impact and financial hit remain unknown; shares fell about 4%.
By: Phalguni Deswal
The UK regulator's review of cobalt-chrome dual-taper modular-neck hip systems from manufacturers like Stryker and Smith+Nephew found heightened wear, corrosion and tissue-reaction risks in about 750 patients. All affected implants had already been withdrawn from the market.
By: Phalguni Deswal
The congress reset where cardiac devices sit in guidelines: Abbott's HeartMate 3 rose to Class I and CardioMEMS to IIa; J&J's Impella won its own category but not the Class I that triggers its Abiomed payout; and new rehab and CVD-CKD frameworks opened lanes for digital health and diagnostics.
By: Phalguni Deswal, Oded Ben-Joseph, David Feygin
Healthcare software beat earnings through H1 2026 and sold off anyway. Outcome Capital argues the market is repricing seat-based software, not management — and that healthcare, forced by regulators to codify how it works, is best placed to capture the agentic value replacing it.
As medtech companies race to feed patient data into diagnostic algorithms and AI models, valuation expert warn that pricing this intangible asset is still far more art than science — and in healthcare, getting the number wrong carries real regulatory risk.
By: Phalguni
Medtronic opened fiscal 2027 with 13.7% Q1 growth powered by an 88% surge in cardiac ablation, and channeled the strength into a ~$700m Cornerstone robotics deal, an up-to-$80m Pi-Cardia structural-heart bet and raised guidance.
By: Phalguni Deswal
FDA reaffirms fluoropolymers such as PTFE are safe and irreplaceable in devices, but the reprieve is US-only: an EU REACH restriction, tighter EPA reporting and supplier exits are already pushing device makers toward PFAS-free alternatives.
By: Phalguni Deswal
The medical device maker says an Aug. 25 cyberattack makes 2026 guidance “unlikely” to be met, sending shares down 5.9%, in a year already marked by a Watchman slowdown.
By: Phalguni Deswal
Bridge to Life closed a $110m Series C to fund a US commercial push for VitaSmart, its cold HOPE perfusion system, betting a simpler, cheaper workflow undercuts NMP rivals — with an FMN viability diagnostic, still in validation, as the intended moat.
